Provider and patient knowledge gaps on biosimilars: insights from surveys.
Gibofsky Allan, Evans Colby, Strand Vibeke·The American journal of managed care
Beyond the legal and regulatory limitations associated with biosimilar availability in the United States, the adoption of biosimilars is contingent on the willingness of health care providers (HCPs) to prescribe them and of patients to accept them. In this dynamic market, it is of paramount importance to understand the…